Abstract:VSMCs (vascular smooth muscle cells) play critical roles in arterial remodelling with aging, hypertension and atherosclerosis. VSMCs exist in diverse phenotypes and exhibit phenotypic plasticity, e.g. changing from a quiescent/contractile phenotype to an active myofibroblast-like, often called 'synthetic', phenotype. Synthetic VSMCs are able to proliferate, migrate and secrete ECM (extracellular matrix) proteinases and ECM proteins. In addition, they produce pro-inflammatory molecules, providing an inflammatory microenvironment for leucocyte penetration, accumulation and activation. The aging VSMCs have also shown changes in cellular phenotype, responsiveness to contracting and relaxing mediators, replicating potential, matrix synthesis, inflammatory mediators and intracellular signalling. VSMC dysfunction plays a key role in age-associated vascular remodelling. Cyclic nucleotide PDEs (phosphodiesterases), by catalysing cyclic nucleotide hydrolysis, play a critical role in regulating the amplitude, duration and compartmentalization of cyclic nucleotide signalling. Abnormal alterations of PDEs and subsequent changes in cyclic nucleotide homoeostasis have been implicated in a number of different diseases. In the study published in the latest issue of Clinical Science, Bautista Niño and colleagues have shown that, in cultured senescent human VSMCs, PDE1A and PDE1C mRNA levels are significantly up-regulated and inhibition of PDE1 activity with vinpocetine reduced cellular senescent makers in senescent VSMCs. Moreover, in the premature aging mice with genomic instability (Ercc1(d/-)), impaired aortic ring relaxation in response to SNP (sodium nitroprusside), an NO (nitric oxide) donor, was also largely improved by vinpocetine. More interestingly, using data from human GWAS (genome-wide association studies), it has been found that PDE1A single nucleotide polymorphisms is significantly associated with diastolic blood pressure and carotid intima-media thickening, two hallmarks of human vascular dysfunction in aging. These findings establish a strong relationship between PDE1 expression regulation and vascular abnormalities in aging.

MAKING UP OR BREAKING UP: THE TORTUOUS ROLE OF PLATELET‐DERIVED GROWTH FACTOR IN VASCULAR AGEING

Recent Progress in Vascular Aging: Mechanisms and Its Role in Age-related Diseases

Endothelial progenitor cells in age-related vascular remodeling.

Age-Related Impairment Of Vascular Structure And Functions

Ageing-exaggerated Proliferation of Vascular Smooth Muscle Cells is Related to Attenuation of Jagged1 Expression in Endothelial Cells.

Oxidative stress-induced cellular senescence desensitizes cell growth and migration of vascular smooth muscle cells through down-regulation of platelet-derived growth factor receptor-beta

Initiation and Propagation of Vascular Calcification Is Regulated by a Concert of Platelet- and Smooth Muscle Cell-Derived Extracellular Vesicles

Vascular aging: Molecular mechanisms and potential treatments for vascular rejuvenation

Epigenetic Regulation of Vascular Aging and Age-Related Vascular Diseases.

The Role and Mechanism of Vascular Aging in Geriatric Vascular Diseases

Endothelial Cell Senescence and Age-Related Vascular Diseases

Cyclic nucleotide phosphodiesterase 1 and vascular aging

The effects of aging, diabetes mellitus, and antiplatelet drugs on growth factors and anti-aging proteins in platelet-rich plasma

Cellular and Molecular Determinants of Arterial Aging

Endothelial dysfunction and angiogenesis impairment in the ageing vasculature

The mechanisms of vascular aging

Vascular Aging and The Corresponding Mechanisms

Endogenous Vasoactive Peptides and Vascular Aging-Related Diseases

Aging Is Associated With Organ-Specific Alterations in the Level and Expression Pattern of von Willebrand Factor

Abstract P2066: Age-related Changes In Posttranscriptional Regulation Of Macrophage VEGF As A Mechanism Of Impaired Inflammatory Arteriogenesis

The disparity of platelet factor 4 and platelets in individuals of different ages